QIAGEN N.V. (QGEN) Stock Price, Quote, News and Overview
NYSE:QGEN - New York Stock Exchange, Inc. - NL0015002CX3 - Common Stock - Currency: USD
QGEN Quote, Performance and Key Statistics
42.11
-0.85 (-1.98%)
The current stock price of QGEN is 42.11 USD. In the past month the price decreased by -0.5%. In the past year, price decreased by -7.84%.
QGEN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 19.59 | 161.92B | ||
| DHR | DANAHER CORP | 26.39 | 140.71B | ||
| A | AGILENT TECHNOLOGIES INC | 21.74 | 32.91B | ||
| IQV | IQVIA HOLDINGS INC | 13.33 | 26.57B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 29.09 | 24.53B | ||
| WAT | WATERS CORP | 30.14 | 21.36B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 32.51 | 15.51B | ||
| ILMN | ILLUMINA INC | 24.11 | 12.71B | ||
| TEM | TEMPUS AI INC | N/A | 11.92B | ||
| RVTY | REVVITY INC | 19.62 | 11.62B | ||
| ICLR | ICON PLC | 10.24 | 11.60B | ||
| AVTR | AVANTOR INC | 13.17 | 9.06B |
Related stock screener links
About QGEN
Company Profile
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company is headquartered in Venlo, Limburg and currently employs 5,765 full-time employees. The firm is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The firm's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Company Info
QIAGEN N.V.
Hulsterweg 82
Venlo LIMBURG 5912 NL
CEO: Thierry Bernard
Employees: 5232
Phone: 31773556600
QIAGEN N.V. / QGEN FAQ
What is the stock price of QIAGEN N.V. today?
The current stock price of QGEN is 42.11 USD. The price decreased by -1.98% in the last trading session.
What is the ticker symbol for QIAGEN N.V. stock?
The exchange symbol of QIAGEN N.V. is QGEN and it is listed on the New York Stock Exchange, Inc. exchange.
On which exchange is QGEN stock listed?
QGEN stock is listed on the New York Stock Exchange, Inc. exchange.
What is the price forecast or stock price prediction for QIAGEN N.V. stock?
25 analysts have analysed QGEN and the average price target is 50.15 USD. This implies a price increase of 19.08% is expected in the next year compared to the current price of 42.11. Check the QIAGEN N.V. stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is QIAGEN N.V. worth?
QIAGEN N.V. (QGEN) has a market capitalization of 9.10B USD. This makes QGEN a Mid Cap stock.
How many employees does QIAGEN N.V. have?
QIAGEN N.V. (QGEN) currently has 5232 employees.
What are the support and resistance levels for QIAGEN N.V. (QGEN) stock?
QIAGEN N.V. (QGEN) has a support level at 38.25 and a resistance level at 42.19. Check the full technical report for a detailed analysis of QGEN support and resistance levels.
Is QIAGEN N.V. (QGEN) expected to grow?
The Revenue of QIAGEN N.V. (QGEN) is expected to grow by 2.97% in the next year. Check the estimates tab for more information on the QGEN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy QIAGEN N.V. (QGEN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of QGEN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of QGEN, evaluating the profitability, health, valuation and growth aspects
- QIAGEN N.V. (QGEN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- QIAGEN N.V. (QGEN) Sales and EPS estimates to see what analysts future expectations are.
- QIAGEN N.V. (QGEN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- QIAGEN N.V. (QGEN) Insider and Institutional Ownership to learn about the owners and their transactions.
- QIAGEN N.V. (QGEN) Stock Chart to make your own analysis
- QIAGEN N.V. (QGEN) Latest news and press-releases to stay up to date.
Does QIAGEN N.V. (QGEN) stock pay dividends?
QIAGEN N.V. (QGEN) has a dividend yield of 0.59%. The yearly dividend amount is currently 0. Check the full fundamental report for a detailed analysis of QGEN dividend history, reliability and sustainability.
When does QIAGEN N.V. (QGEN) report earnings?
QIAGEN N.V. (QGEN) will report earnings on 2025-07-31, after the market close.
What is the Price/Earnings (PE) ratio of QIAGEN N.V. (QGEN)?
The PE ratio for QIAGEN N.V. (QGEN) is 18.31. This is based on the reported non-GAAP earnings per share of 2.3 and the current share price of 42.11 USD. Check the full fundamental report for a full analysis of the valuation metrics for QGEN.
What is the Short Interest ratio of QIAGEN N.V. (QGEN) stock?
The outstanding short interest for QIAGEN N.V. (QGEN) is 2.38% of its float. Check the ownership tab for more information on the QGEN short interest.
QGEN Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to QGEN. When comparing the yearly performance of all stocks, QGEN turns out to be only a medium performer in the overall market: it outperformed 47.48% of all stocks.
QGEN Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to QGEN. QGEN has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
QGEN Financial Highlights
Over the last trailing twelve months QGEN reported a non-GAAP Earnings per Share(EPS) of 2.3. The EPS increased by 11.95% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 4.23% | ||
| ROA | 1.47% | ||
| ROE | 2.34% | ||
| Debt/Equity | 0.38 |
QGEN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 76% to QGEN. The Buy consensus is the average rating of analysts ratings from 25 analysts.
For the next year, analysts expect an EPS growth of 5.89% and a revenue growth 2.97% for QGEN